Loading...

Adverum Biotechnologies

DB:AVU
Snowflake Description

Excellent balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
AVU
DB
$378M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, engages in developing gene therapy product candidates to treat ocular and rare diseases. The last earnings update was 46 days ago. More info.


Add to Portfolio Compare Print
  • Adverum Biotechnologies has significant price volatility in the past 3 months.
AVU Share Price and Events
7 Day Returns
13.5%
DB:AVU
-2.4%
DE Biotechs
1.8%
DE Market
1 Year Returns
1.9%
DB:AVU
-10.2%
DE Biotechs
-6%
DE Market
AVU Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Adverum Biotechnologies (AVU) 13.5% 8.6% 89.2% 1.9% -0.5% -
DE Biotechs -2.4% 3.2% -7.7% -10.2% 51.2% 10.1%
DE Market 1.8% 4.6% 7.4% -6% 10.1% 15.3%
1 Year Return vs Industry and Market
  • AVU outperformed the Biotechs industry which returned -10.2% over the past year.
  • AVU outperformed the Market in Germany which returned -6% over the past year.
Price Volatility
AVU
Industry
5yr Volatility vs Market
Related Companies

AVU Value

 Is Adverum Biotechnologies undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Adverum Biotechnologies. This is due to cash flow or dividend data being unavailable. The share price is €5.28.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Adverum Biotechnologies's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Adverum Biotechnologies's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:AVU PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-1.18
NasdaqGM:ADVM Share Price ** NasdaqGM (2019-04-18) in USD $5.98
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.44x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.59x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Adverum Biotechnologies.

DB:AVU PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:ADVM Share Price ÷ EPS (both in USD)

= 5.98 ÷ -1.18

-5.05x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Adverum Biotechnologies is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Adverum Biotechnologies is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Adverum Biotechnologies's expected growth come at a high price?
Raw Data
DB:AVU PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -5.05x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts
-7.4%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Adverum Biotechnologies, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Adverum Biotechnologies's assets?
Raw Data
DB:AVU PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $3.19
NasdaqGM:ADVM Share Price * NasdaqGM (2019-04-18) in USD $5.98
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.84x
DB:AVU PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:ADVM Share Price ÷ Book Value per Share (both in USD)

= 5.98 ÷ 3.19

1.87x

* Primary Listing of Adverum Biotechnologies.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Adverum Biotechnologies is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Adverum Biotechnologies's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Adverum Biotechnologies has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

AVU Future Performance

 How is Adverum Biotechnologies expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-7.4%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Adverum Biotechnologies expected to grow at an attractive rate?
  • Unable to compare Adverum Biotechnologies's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Adverum Biotechnologies's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Adverum Biotechnologies's revenues are expected to decrease over the next 1-3 years, this is below the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:AVU Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:AVU Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts -7.4%
DB:AVU Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 4 Analysts -10.1%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:AVU Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:AVU Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 1 -105 2
2022-12-31 1 -91 2
2021-12-31 1 -84 3
2020-12-31 2 -79 4
2019-12-31 1 -71 4
DB:AVU Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 2 -54 -73
2018-09-30 2 -53 -72
2018-06-30 2 -47 -65
2018-03-31 2 -47 -57
2017-12-31 2 -45 -56
2017-09-30 2 -42 -64
2017-06-30 2 -41 -64
2017-03-31 2 -38 -114
2016-12-31 1 -38 -114
2016-09-30 2 -39 -105
2016-06-30 2 -39 -105
2016-03-31 2 -40 -53

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Adverum Biotechnologies is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Adverum Biotechnologies's revenue is expected to decrease over the next 1-3 years, this is not considered high growth.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:AVU Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below

All data from Adverum Biotechnologies Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:AVU Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 -1.37 -1.25 -1.50 3.00
2022-12-31 -1.22 -1.10 -1.37 3.00
2021-12-31 -1.24 -1.15 -1.38 4.00
2020-12-31 -1.20 -1.05 -1.35 5.00
2019-12-31 -1.13 -1.07 -1.20 5.00
DB:AVU Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -1.18
2018-09-30 -1.26
2018-06-30 -1.24
2018-03-31 -1.21
2017-12-31 -1.29
2017-09-30 -1.50
2017-06-30 -1.52
2017-03-31 -2.86
2016-12-31 -3.14
2016-09-30 -3.27
2016-06-30 -3.72
2016-03-31 -2.05

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Adverum Biotechnologies will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Adverum Biotechnologies's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Adverum Biotechnologies has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

AVU Past Performance

  How has Adverum Biotechnologies performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Adverum Biotechnologies's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Adverum Biotechnologies does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Adverum Biotechnologies's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Adverum Biotechnologies's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Adverum Biotechnologies's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Adverum Biotechnologies Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:AVU Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 1.61 -72.63 18.76
2018-09-30 2.00 -71.76 18.42
2018-06-30 1.63 -64.63 19.35
2018-03-31 1.60 -57.25 19.24
2017-12-31 1.85 -56.15 19.86
2017-09-30 1.88 -63.75 21.59
2017-06-30 1.81 -64.22 21.58
2017-03-31 1.65 -114.45 19.83
2016-12-31 1.46 -113.75 20.36
2016-09-30 1.93 -105.45 18.55
2016-06-30 2.49 -105.23 20.44
2016-03-31 2.38 -53.34 23.08
2015-12-31 2.32 -47.45 19.71
2015-09-30 1.56 -43.75 20.11
2015-06-30 0.81 -37.92 14.88
2015-03-31 0.75 -36.48 11.42
2014-12-31 0.57 -28.63 8.00
2014-09-30 0.37 -21.94 5.01
2014-06-30 0.20 -14.49 2.87
2014-03-31 0.21 -6.89 1.57
2013-12-31 0.48 -5.28 0.98
2012-12-31 0.03 -1.81 0.54

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Adverum Biotechnologies has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Adverum Biotechnologies has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Adverum Biotechnologies improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Adverum Biotechnologies's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Adverum Biotechnologies has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

AVU Health

 How is Adverum Biotechnologies's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Adverum Biotechnologies's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Adverum Biotechnologies is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Adverum Biotechnologies's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Adverum Biotechnologies's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 1043.8x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Adverum Biotechnologies Company Filings, last reported 3 months ago.

DB:AVU Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 201.17 0.20 205.08
2018-09-30 215.55 0.00 217.88
2018-06-30 233.45 0.00 234.88
2018-03-31 246.04 0.00 247.04
2017-12-31 184.03 0.46 190.49
2017-09-30 180.99 0.07 186.64
2017-06-30 192.18 0.07 197.42
2017-03-31 201.38 0.07 209.50
2016-12-31 215.60 0.07 222.17
2016-09-30 236.23 0.07 231.27
2016-06-30 247.65 0.00 241.30
2016-03-31 241.57 0.00 247.08
2015-12-31 252.59 0.00 259.08
2015-09-30 262.33 0.00 268.89
2015-06-30 270.63 0.00 279.64
2015-03-31 279.68 0.00 290.13
2014-12-31 149.48 0.00 159.40
2014-09-30 155.74 0.00 165.33
2014-06-30 43.60 0.00 52.43
2014-03-31 49.91 0.01 50.68
2013-12-31 -0.13 0.00 0.56
2012-12-31 -0.96 0.49 0.36
  • Adverum Biotechnologies's level of debt (0.1%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (0% vs 0.1% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Adverum Biotechnologies has sufficient cash runway for more than 3 years based on current free cash flow.
  • Adverum Biotechnologies has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 10.6% each year.
X
Financial health checks
We assess Adverum Biotechnologies's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Adverum Biotechnologies has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

AVU Dividends

 What is Adverum Biotechnologies's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Adverum Biotechnologies dividends.
If you bought €2,000 of Adverum Biotechnologies shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Adverum Biotechnologies's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Adverum Biotechnologies's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:AVU Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:AVU Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Adverum Biotechnologies has not reported any payouts.
  • Unable to verify if Adverum Biotechnologies's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Adverum Biotechnologies's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Adverum Biotechnologies has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Adverum Biotechnologies's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Adverum Biotechnologies afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Adverum Biotechnologies has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

AVU Management

 What is the CEO of Adverum Biotechnologies's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Leone Patterson
AGE 55
TENURE AS CEO 0.9 years
CEO Bio

Ms. Leone D. Patterson serves as the Chief Executive Officer and Director of Adverum Biotechnologies, Inc. since October 12, 2018. Ms. Patterson has been the Chief Financial Officer at Adverum Biotechnologies, Inc. since June 15, 2016 and served as Senior Vice President since February 2018 until May 3, 2018. She served as the President of Adverum Biotechnologies, Inc. since October 12, 2018 until November 2018. She served as the Interim President and Chief Executive Officer of Adverum Biotechnologies, Inc. since May 3, 2018 until October 12, 2018. Ms. Patterson has more than 20 years of Finance and Accounting experience. Ms. Patterson served as the Chief Financial Officer of Diadexus, Inc. from March 16, 2015 to June 10, 2016. Ms. Patterson served as the Chief Financial Officer and Vice President of Transcept Pharmaceuticals, Inc. from June 25, 2012 to October 30, 2014. Ms. Patterson served as Chief Financial Officer and Vice President of Paratek Pharmaceuticals, Inc. until October 30, 2014. She served as Principal Accounting Officer at Transcept Pharmaceuticals, Inc. From November 2010 to June 2012, she served as a Vice President and Corporate Controller at Net App. From November 2010 to June 2012, Ms. Patterson served as Vice President and Global Corporate Controller of NetApp, Inc. From July 2007 to November 2010, she served as Vice President of Finance at Exelixis. Ms. Patterson served as Vice President of Global Business Planning Analysis of the Vaccines and Diagnostics Division at Novartis AG from April 2006 to July 2007, where she oversaw the business planning and analysis function for the Vaccines and Diagnostics Division. From 1999 to 2006, She held several positions at Chiron, Corp., including as its Vice President since November 2003 and Corporate Controller since 2001. Ms. Patterson joined Chiron Corporation in 1999 as Director of Special Projects in the corporate finance group. Ms. Patterson worked at KPMG LLP as a Senior Manager in the San Francisco audit practice for two years. She served at KPMG LLP from 1989 to 1999. She served with KPMG Auckland in the New Zealand audit practice for eight years. Ms. Patterson was a Certified Public Accountant. Ms. Patterson received a B.S. degree in Business Administration and Accounting from Chapman University and an Executive M.B.A. and graduated with honors from St. Mary's College. Ms. Patterson is also a Certified Public Accountant (inactive status).

CEO Compensation
  • Insufficient data for Leone to compare compensation growth.
  • Insufficient data for Leone to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Adverum Biotechnologies management team in years:

0.9
Average Tenure
55
Average Age
  • The average tenure for the Adverum Biotechnologies management team is less than 2 years, this suggests a new team.
Management Team

Mehdi Gasmi

TITLE
President & Chief Scientific Officer
COMPENSATION
$1M
AGE
51
TENURE
0.4 yrs

Mitch Finer

TITLE
Co-Founder & Director
COMPENSATION
$167K
AGE
59

Amber Salzman

TITLE
Consultant
COMPENSATION
$2M
AGE
56
TENURE
0.9 yrs

Leone Patterson

TITLE
CEO, CFO & Director
AGE
55
TENURE
0.9 yrs

Jennifer Cheng

TITLE
VP, General Counsel & Corporate Secretary
AGE
45
TENURE
2.2 yrs

Aaron Osborne

TITLE
Chief Medical Officer
Board of Directors Tenure

Average tenure and age of the Adverum Biotechnologies board of directors in years:

2.1
Average Tenure
59
Average Age
  • The average tenure for the Adverum Biotechnologies board of directors is less than 3 years, this suggests a new board.
Board of Directors

Paul Cleveland

TITLE
Chairman
COMPENSATION
$981K
AGE
61
TENURE
2.5 yrs

Mitch Finer

TITLE
Co-Founder & Director
COMPENSATION
$167K
AGE
59
TENURE
2.9 yrs

Leone Patterson

TITLE
CEO, CFO & Director
AGE
55
TENURE
0.5 yrs

Pat Machado

TITLE
Director
COMPENSATION
$428K
AGE
54
TENURE
2.1 yrs

Richard Spivey

TITLE
Director
COMPENSATION
$424K
AGE
68
TENURE
2 yrs

Tom Woiwode

TITLE
Director
COMPENSATION
$223K
AGE
46
TENURE
2.9 yrs

Eric Carter

TITLE
Director
COMPENSATION
$279K
AGE
66
TENURE
1.6 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
21. Mar 19 Buy The Sonic Fund II, L.P. Company 30. Jan 19 19. Mar 19 1,418,449 €5.02 €7,114,403
X
Management checks
We assess Adverum Biotechnologies's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Adverum Biotechnologies has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

AVU News

Simply Wall St News

AVU Company Info

Description

Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, engages in developing gene therapy product candidates to treat ocular and rare diseases. Its pipeline of product candidates includes ADVM-022, an adeno- associated virus (AAV). 7m8-aflibercept for the treatment of wet age-related macular degeneration; ADVM-043, an investigational gene therapy candidate for the treatment of alpha-1 antitrypsin deficiency; and ADVM-053, a preclinical gene therapy product candidate for the treatment of hereditary angioedema. The company has collaboration agreements with Editas Medicine, Inc. to leverage its proprietary AAV vectors for genome editing technologies to treat up to five inherited retinal diseases; and Regeneron Pharmaceuticals, Inc. for the development of up to eight distinct ocular therapeutic targets. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was founded in 2006 and is headquartered in Menlo Park, California.

Details
Name: Adverum Biotechnologies, Inc.
AVU
Exchange: DB
Founded: 2006
$336,066,056
63,201,009
Website: http://www.adverum.com
Address: Adverum Biotechnologies, Inc.
1035 O’Brien Drive,
Suite A,
Menlo Park,
California, 94025,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM ADVM Common Stock Nasdaq Global Market US USD 01. Aug 2014
DB AVU Common Stock Deutsche Boerse AG DE EUR 01. Aug 2014
LSE 0HA3 Common Stock London Stock Exchange GB USD 01. Aug 2014
Number of employees
Current staff
Staff numbers
82
Adverum Biotechnologies employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/21 21:43
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/15
Last earnings filing: 2019/03/06
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.